Intrapleural administration of TolueneSulfonamide

Phase 2Small molecule

Intrapleural administration of TolueneSulfonamide is one of 7 small molecule programs targeting Pleural effusion. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural EffusionNot yet recruiting

Pleural EffusionPhase 2

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Pleural Effusion

#DrugCompanyPhaseTrials

Sclerosol

SSciarra

Approved

3 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Interleukin-2 (IL2)

Astellas

Phase 1

1 4

Intrapleural administration of TolueneSulfonamide

GGang Hou

Phase 2

1 5

JMKX000197

JJemincare

Phase 1

2 6

Intrapleural Medications

SSwedish Medical Center

Preclinical

1 7

Recombinant Human Interleukin-2

SSecond Xiangya Hospital of Central South University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Not yet recruiting

Pleural Effusion

NCT07332858

Clinical

Trials by Indication[1]

Pleural effusion1 trial

First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion

Not yet recruiting·GGang Hou·Phase 1/2·NCT07332858·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intrapleural administration of TolueneSulfonamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrapleural administration of TolueneSulfonamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrapleural administration of TolueneSulfonamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gang Hou company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGang Hou

Intrapleural administration of TolueneSulfonamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pleural effusion1 trial

References

Drug Info

Quick Facts

Related News